PMID- 22085387
OWN - NLM
STAT- MEDLINE
DCOM- 20120716
LR  - 20211021
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 71
IP  - 17
DP  - 2011 Dec 3
TI  - Current status of targeted therapies for mantle cell lymphoma.
PG  - 2307-26
LID - 10.2165/11594630-000000000-00000 [doi]
AB  - Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL) with 
      treatment outcomes that have historically been poorer than those observed with 
      other NHL subtypes. Patients typically present with advanced-stage disease and 
      frequent extranodal involvement; the median age at diagnosis is >60 years. Recent 
      improvements in progression-free and overall survival have been observed with 
      more dose-intensive strategies, although at least half of patients diagnosed with 
      MCL are not eligible for such treatment approaches based on age and 
      co-morbidities. In addition, therapy options for relapsed MCL are limited. Only 
      bortezomib is approved for treatment of relapsed MCL in the US. Development of 
      targeted therapy approaches to minimize toxicities while preserving 
      anti-neoplastic properties is of particular importance in MCL. Multiple ongoing 
      studies are attempting to build on the known efficacy of bortezomib by evaluating 
      combination regimens with other targeted agents or cytotoxic chemotherapy. The 
      mammalian target of rapamycin (mTOR) inhibitor temsirolimus has known activity in 
      MCL, making this an attractive class of agents for further investigation in 
      combination regimens. Rituximab and other monoclonal antibodies are being 
      evaluated for novel roles in MCL treatment, including as maintenance therapy. 
      Other classes of drugs being investigated in MCL are immunomodulatory agents, 
      inhibitors of the phosphoinositide 3-kinase/Akt and B-cell receptor signalling 
      pathways, and inhibitors of bcl-2 and histone deacetylase. Although many of the 
      agents appear to have modest single-agent activity, the favourable toxicity 
      profile of many agents will make them best suited for incorporation into 
      combination regimens.
FAU - Chang, Julie E
AU  - Chang JE
AD  - Department of Medicine, University of Wisconsin School of Medicine and Public 
      Health, Madison, WI 53705, USA. jc2@medicine.wisc.edu
FAU - Kahl, Brad S
AU  - Kahl BS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/adverse 
      effects/pharmacology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Lymphoma, Mantle-Cell/*drug therapy
MH  - Molecular Targeted Therapy/adverse effects/*methods
EDAT- 2011/11/17 06:00
MHDA- 2012/07/17 06:00
CRDT- 2011/11/17 06:00
PHST- 2011/11/17 06:00 [entrez]
PHST- 2011/11/17 06:00 [pubmed]
PHST- 2012/07/17 06:00 [medline]
AID - 6 [pii]
AID - 10.2165/11594630-000000000-00000 [doi]
PST - ppublish
SO  - Drugs. 2011 Dec 3;71(17):2307-26. doi: 10.2165/11594630-000000000-00000.